Histiocytic cytophagic panniculitis which developed during interferon-alpha therapy.
A 59-year-old woman developed edema of the face and eyelids during interferon (IFN)-alpha-2b therapy for chronic hepatitis C with a cumulative dose of 6 million x 47 units. Despite cessation of the therapy, the edema progressed and was followed by exophthalmos, pyrexia, liver dysfunction, pancytopenia, and disseminated intravascular coagulation. Two months after initial presentation, she died of hemorrhagic shock and was diagnosed with histiocytic cytophagic panniculitis at autopsy. This may be a hitherto unrecognized adverse effect of therapeutic IFN alpha.
Kuno
M
M
Department of Pathology, Jichi Medical School, Tochigi.
Mimori
A
A
Fujii
T
T
Takeda
A
A
Masuyama
J
J
Yoshio
T
T
Minota
S
S
Kano
S
S
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D002908:Chronic Disease; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D005094:Exophthalmos / Q000139:chemically induced; D005141:Eyelid Diseases / Q000139:chemically induced; D005145:Face / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D005334:Fever / Q000139:chemically induced; D006526:Hepatitis C / Q000628:therapy; D006644:Histiocytes / Q000473:pathology*; D015614:Histiocytosis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D010587:Phagocytosis; D011994:Recombinant Proteins; D012771:Shock, Hemorrhagic / Q000401:mortality
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins